The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial

Anthony G. Marson, Asya M. Al-Kharusi, Muna Alwaidh, Richard Appleton, Gus A. Baker, David W. Chadwick, Celia Cramp, Oliver C. Cockerell, Paul N. Cooper, Julie Doughty, Barbara Eaton, Carrol Gamble, Peter J. Goulding, Stephen JL Howell, Adrian Hughes, Margaret Jackson, Ann Jacoby, Mark Kellett, Geoffrey R. Lawson, John Paul LeachPaola Nicolaides, Richard Roberts, Phil Shackley, Jing Shen, David F. Smith, Philip EM Smith, Catrin Tudur Smith, Alessandra Vanoli, Paula R. Williamson

Research output: Contribution to journalArticle

599 Citations (Scopus)

Abstract

Background: Carbamazepine is widely accepted as a drug of first choice for patients with partial onset seizures. Several newer drugs possess efficacy against these seizure types but previous randomised controlled trials have failed to inform a choice between these drugs. We aimed to assess efficacy with regards to longer-term outcomes, quality of life, and health economic outcomes. Methods: SANAD was an unblinded randomised controlled trial in hospital-based outpatient clinics in the UK. Arm A recruited 1721 patients for whom carbamazepine was deemed to be standard treatment, and they were randomly assigned to receive carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate. Primary outcomes were time to treatment failure, and time to 12-months remission, and assessment was by both intention to treat and per protocol. This study is registered as an International Standard Randomised Controlled Trial, number ISRCTN38354748. Findings: For time to treatment failure, lamotrigine was significantly better than carbamazepine (hazard ratio [HR] 0·78 [95% CI 0·63-0·97]), gabapentin (0·65 [0·52-0·80]), and topiramate (0·64 [0·52-0·79]), and had a non-significant advantage compared with oxcarbazepine (1·15 [0·86-1·54]). For time to 12-month remission carbamazepine was significantly better than gabapentin (0·75 [0·63-0·90]), and estimates suggest a non-significant advantage for carbamazepine against lamotrigine (0·91 [0·77-1·09]), topiramate (0·86 [0·72-1·03]), and oxcarbazepine (0·92 [0·73-1·18]). In a per-protocol analysis, at 2 and 4 years the difference (95% CI) in the proportion achieving a 12-month remission (lamotrigine-carbamazepine) is 0 (-8 to 7) and 5 (-3 to 12), suggesting non-inferiority of lamotrigine compared with carbamazepine. Interpretation: Lamotrigine is clinically better than carbamazepine, the standard drug treatment, for time to treatment failure outcomes and is therefore a cost-effective alternative for patients diagnosed with partial onset seizures.

Original languageEnglish
Pages (from-to)1000-1015
Number of pages16
JournalLancet
Volume369
Issue number9566
DOIs
Publication statusPublished - 24 Mar 2007

Fingerprint Dive into the research topics of 'The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial'. Together they form a unique fingerprint.

  • Cite this

    Marson, A. G., Al-Kharusi, A. M., Alwaidh, M., Appleton, R., Baker, G. A., Chadwick, D. W., Cramp, C., Cockerell, O. C., Cooper, P. N., Doughty, J., Eaton, B., Gamble, C., Goulding, P. J., Howell, S. JL., Hughes, A., Jackson, M., Jacoby, A., Kellett, M., Lawson, G. R., ... Williamson, P. R. (2007). The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet, 369(9566), 1000-1015. https://doi.org/10.1016/S0140-6736(07)60460-7